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ABSTRACT 
Background: Vaginosis is a widely prevalent syndrome in women. Treatment with 
one or more antibiotics cures invariably the infections. However recurrence is 
frequent and pH of the vagina is not always restored to the normal acidic range. This 
trial was conducted to determine whether a Polyherbal Microbicide BASANT or three 
selected strains of Probiotics Lactobacilli alone or the two in combination can regress 
Vaginosis, bring down the vaginal pH to acidic range and restore healthy vagina with 
colonised Lactobacilli. 
Methods: Women suffering from recurrent episodes of vaginosis were given 
capsules of either BASANT, Probiotics, Combination of the two or Placebo capsules 
for insertion in vagina for 7 nights. On day 10, Pelvic examination, pH, Whiff test, 
Gram stain for Clue cells and swab taken for culture of lactobacilli. 
Results: BASANT regressed Vaginosis in 14/ 20, Probiotics in 13/20, Combination of 
the two in 19/ 20 women and Placebo in 1/ 20 women. 
Conclusion: While both Polyherbal microbicide BASANT and the three strains of the 
lactobacilli cured Vaginosis in 65 to 70% of women, the combination was highly 
effective in curing 95% of women. 
KEYWORDS: Vaginosis, BASANT, Pro-vag-Health Probiotics, pH, Colonisation. 
INTRODUCTION 
Vaginosis is a widely prevalent 
syndrome. As per an Indian Council of Medical 
Research (ICMR) study, the prevalence of this 
syndrome is about 30% in women attending the 
antenatal clinics in urban Delhi[1]. Bang et al[2] 
reported its incidence to be 50% in rural 
Maharashtra. Its incidence was 80% in slums of 
Delhi in a survey conducted by us along with 
Safdarjung Hospital and Population Foundation 
of India[3]. It is frequently accompanied by 
itching and malodour. The present treatment 
for Bacterial vaginosis employs various 
antibiotics which have different spectrum of 
activity with a cure rate at 4 weeks of 60%–
70%[4].In another study of treatment with 
Metronidazole, 58% women had a recurrence of 
Bacterial vaginosis[5].Invariably this 
uncomfortable syndrome is accompanied by the 
pH of vagina rising above 5, indicative of the 
paucity or absence of lactic acid producing 
strains of Lactobacilli. 
A Polyherbal Microbicide BASANT was 
developed which has inhibitory action on a wide 
spectrum of genital pathogens. BASANT inhibits 
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the growth of WHO strains and clinical isolates 
of Neisseria gonorrhoeae, including those 
resistant to Penicillin, Tetracycline, Nalidixic 
acid and Ciprofloxacin[6]. It has pronounced 
inhibitory action against Candida glabrata, 
Candida albicans and Candida tropicalis isolated 
from women with vulvovaginal candidiasis, 
including three isolates resistant to azole drugs 
and amphotericin. BASANT has a high virucidal 
action against human immunodeficiency virus. 
It inhibits also the entry in Hela cells of 
HPV16[6]. It has inhibitory action on free as well 
as cell-infected Chlamydia trachomatis[7]. 
BASANT was found to be totally safe according 
to pre-clinical toxicology carried out as per 
USFDA recommendations on rabbit vagina after 
application for 7 consecutive days or twice daily 
for 3 weeks. 
We reported previously the isolation of 
80 strains of lactobacilli from healthy 
vagina[8].Amongst these were strains which 
were either high or low producers of lactic 
acid[9].There was marked variation in their 
ability to make and secrete in quantitative 
terms hydrogen peroxide; their degree of 
hydrophobicity and other metabolic 
characteristics. Three strains namely TRF#36 
strain of Lactobacillus fermentum, TRF#8 strain 
of L. gasseri, and TRF#30 strain of L. salivarius 
were selected on basis of their ability to make 
large amount of lactic acid, high hydrophobicity, 
positivity for arginine deiminase, thereby 
competence to prevent the formation of foul 
odour derivatives. 
With the permission of The Drugs 
Controller General of India and with the 
approval of Institutional Ethics Committees, 
trials were conducted in two Institutions to 
determine the ability of BASANT and the 
selected Lactobacilli strains to regress vaginosis 
in women. Besides testing the ability of these 
two individually, the efficacy of using 
combination of the two was also evaluated. 
Controls were taken, with Placebo capsules to 
assess the normal regression of the symptoms 
without treatment. This communication reports 
the findings. 
MATERIALS 
BASANT is a Polyherbal microbicide 
containing 95% purified diferuloyl methane {(E, 
E)-1, 7-bis (4-hydroxy-3-methoxyphenyl)-1, 6 -
heptadiene-3, 5-dione} (Curcumin) from 
Curcuma longa, purified extract of Amla 
(Emblica officinalis), purified extract of Neem 
(Azadirachta indica) leaves, and Aloevera (Aloe 
barbadensis) extract. These ingredients are 
formulated in pharmacopoeially approved 
excipients: Citric Acid, Sorbitol, Microcrystalline 
Cellulose, Sodium Starchglycolate, Starlac, 
Crospovidones and Sodium alginate as a 
lubricating agent. 250 mg BASANT was 
dispensed as powder in cellulose capsules. 
PROBIOTICS, L. fermentum (TRF#36), L. 
gasseri (TRF#8), and L. salivarius (TRF#30) 
were grown on a large scale by M/S Microbax, 
Hyderabad and made available in lyophilized 
form packed in cellulose capsules along with 
Prebiotics. The capsules utilized in the trial 
contained 3×109 of triple combination of L. 
fermentum (TRF#36), L. gasseri (TRF#8) & L. 
salivarius (TRF#30) (here after termed as Pro-
veg-Health). These strains of Lactobacilli have 
been deposited in the National Depository at 
Institute of Microbial Technology Chandigarh, 
who have given them the following numbers: 
Lactobacillus gasseri (TRF #8) MTCC 5615, 
Lactobacillus salivarius (TRF#30) MTCC 5616, 
Lactobacillus fermentum (TRF#36) MTCC 5617. 
MRS (deMan, Rogosa, and Sharpe) Broth 
and Agar (Hi-Media, India) were used for 
culture with Bromo-cresol purple (BCP, Merck, 
India), a colour indicator dye with pH range of 
5.2- 6.8, the colour turns from purple to yellow 
with lowering of pH, enabling ready recognition 
of lactobacilli colonies. 
The pH indicator strips were from EMD 
Chemicals, Gibbstown N.J. (USA), Associate of 
Merck KGaA, Darmstadt, Germany. The strips 
utilized for evaluating vaginal pH had pH range 
of 2.0 to 9.0. The pH above 5 and below 5 could 
be clearly visualized by colour change in one of 
the three rows 
METHODS 
Bacterial vaginosis was diagnosed 
clinically and by Amsel’s criteria[10] for the 
presence of clue cells. Wet mount was prepared 
by directly taking discharge on a slide and 
adding one drop of 10 percent KOH to detect 
fishy odour (Whiff Test). 
Gram staining & Catalase test 
Lactobacillus bacteria are Gram positive 
and catalase negative. Gram staining was done 
by the standard method. Catalase test was done 
by pouring a drop of H2O2 on a colony. Absence 
of oxygen bubble formation indicated absence 
of catalase. Gram positive, catalase negative 
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colonies were cultured individually in MRS 
broth and stored in 20% glycerol at -200C. 
Isolation of Lactobacilli from vaginal swab 
Vaginal swabs in sterile tubes containing 
MRS Broth were brought to laboratory from the 
clinics. The sample was incubated at 37oC 
overnight. The swab was spread on BCP-MRS 
agar plate and incubated at 37°; the colonies 
producing lactic acid were identifiable by the 
yellow colour. 
DNA extraction[11] 
DNA was extracted as per Pospiech el al[11]. 
Genus and Species Identification[12] 
Genus and Species identification as per 
Song et al[12]. Each isolate was identified to the 
genus level by Polymerase Chain Reaction (PCR) 
with genus specific primer LbLMA-rev (5’ CTC 
AAA ACT AAA CAA AGT TTC 3’) and a universal 
primer R16-1 (5’ CTT GTA CAC ACC GCC CGT 
TCA 3’). 
Species level identification was done 
with species specific primers of L. fermentum, L. 
gasseri, and L. salivarius. PCR program and 
reaction mixture was the same as for PCR-genus 
except annealing temperature which was 65oC 
for L. gasseri (360 bp amplicon), and 60oC for L. 
fermentum (192bp amplicon), and L. salivarius 
(411 bp amplicon). Following species specific 
primers were used: 
L. fermentum  
Lfer-3 : 5’ACTAACTTGACTGATCTACGA3’ 
Lfer-4 : 5’ TTCACTGCTCAAGTAATCATC 3’ 
L. salivarius 
Lsal-1 : 5’ AATCGCTAAACTCATAACCT 3’ 
Lsal-2 : 5’ CACTCTCTTTGGCTAATCTT 3’ 
L. gasseri 
Lgas-3 : 5’ AGCGACCGAGAAGAGAGAGA 3’ 
Lgas-2 : 5’ TGCTATCGCTTCAAGTGCTT 3’ 
Amplicons were analysed by electrophoresis in 
2% agars gel followed by ethidium bromide 
staining. 
SUBJECTS & PROTOCOL  
The criteria for enrolment of subjects 
were: Women between 18-45 years of age 
having regular cycles, clinical history of chronic 
and/ or recurring episodes of Bacterial 
vaginosis, willing to participate in the study 
after having been explained about the nature of 
the study and willing to return for follow up 
after 10 days of insertion of capsules and 
thereafter on monthly basis for 2 months or 
more. Women connectable at home by phone 
were given preference for enrolment in the trial, 
which enabled crosscheck of side effects if any 
after insertion of the capsules. The Exclusion 
Criteria were: known cases of diabetes mellitus 
and other systemic diseases including immuno-
compromised states, suspected/confirmed 
pregnancy, suspected or known malignancy of 
reproductive tract, dysfunctional uterine 
bleeding, vaginal polyp and those less than 6 
weeks since last delivery or abortion. Also 
excluded were those with severe allergic 
reactions and abnormality of vaginal anatomy 
likely to interfere with placement of drug, 
adnexal mass or tenderness and those having 
received a course of antibiotic therapy, less than 
14 days prior to enrolment. 
Eighty women were enrolled with 
history of repeated episodes of vaginosis, based 
on clinical symptoms like, thin, white, 
homogeneous discharge, Clue cells on 
microscopy of wet mount, pH of vaginal fluid 
>5.0 and release of fishy odour on adding alkali 
(10% KOH).The subjects were serially assigned 
to one of the four groups. 
Group I was given 7 capsules of triple 
combination of Probiotics to be used one 
capsules of 3x109 Lactobacilli every night for a 
week. Group II was given 7 capsules of 
BASANT,one capsule to be taken every night for 
a week, Group III received combination of 7 
capsules of BASANT and 7 capsules of 
Probiotics (combination hereafter termed as 
NAUROZ) to be used every night for a week and 
Group IV were controls who received 7 capsules 
of Placebo, one capsule every night for a 
week.On day 3, their experience of intravaginal 
insertion of the given capsules was asked by 
telephone and also, whether any side effects 
experienced. They were told to report to the 
clinic on day 10, when reexamination was done 
on the status of the discharge & other symptoms 
of vaginosis.Also recorded was the degree of 
relief experienced by the woman, pH was 
recorded and swab sample taken for 
culture.They were then given one capsule of the 
same to be taken once every week as 
maintenance regime. Their status was observed 
on repeat visits to the clinic or by telephone for 
atleast two months. 
RESULTS 
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In group I women using Probiotics, 13 
out of 20 (65%) were classifiable in effective 
category whereas 7 out of 20 did not respond to 
this treatment. Table 1 is an illustrative example 
of observations on a subject responding 
effectively to treatment with Probiotics and 
Table 2 represents a case in which treatment 
with Probiotics alone was not effective. While 
all 80 women enrolled in the trial reported to 
the clinic on day 10, thereafter those benefited 
continued to come at periodic intervals for 
receiving maintenance dose capsules to be 
taken once every week, Women who were not 
benefited ceased to come after some time and 
could be considered to be lost to follow up. All 
women enrolled however took for 7 days the 
prescribed capsules, reported on day 10 to the 
clinic for examination & thereafter received 2 
maintenance capsules, one to be taken every 
week for the following two weeks. 
Table 1: SUBJECT BV-A-95:- FALLING IN “EFFECTIVE” CATEGORY OF GROUP I GIVEN 7 
CAPSULES OF PRO-VAG-HEALTH ONE CAPSULE EVERY NIGHT FOR 7 DAYS. 
Patient ID 
BV-A-95 
Initial On 
Enrollment 
1st Follow Up 
(Day 10) 
2nd Follow Up 
(Day 31) 
3rd Follow Up 
 (Day 66) 
4th Follow Up 
(Day 83) 
Date 22/03/12 02/04/12 23/04/12 28/05/12 14/06/12 
Discharge 
Amount 
+++ + _ _ _ 
pH 5.0 4.5 5.0 4.5 4.5 
Odour + _ _ _ _ 
Itching/burning _ _ _ _ _ 
Clue Cells + _ _ _ _ 
Lactobacilli 
growth 
_ + + + + 
Prescription 
 
Pro-vag-Health 
(7 capsules) 
Pro-vag-
Health (2 
capsules) one 
each week 
Pro-vag-Health 
(2 capsules) 
One each week 
Pro-vag-Health 
(2 capsules) 
One each week 
Pro-vag-Health 
(2 capsules) 
One each week 
Subjective 
Relief 
_ 95% Relief 100% Relief 100% Relief Patient Satisfied 
Side effects  None None None None 
“+” Present, “-“Absent 
Table 2: SUBJECT BV-A-111:- FALLING IN “ NOT-EFFECTIVE” CATEGORY OF GROUP I GIVEN 7 
CAPSULES OF PRO-VAG-HEALTH ONE CAPSULE EVERY NIGHT FOR 7 DAYS. 
Patient ID 
BV-A-110 
Initial On 
Enrollment 
1st Follow Up 
(Day 14) 
2nd Follow Up 
(Day 31) 
Date 09/04/12 23/04/12 10/05/12 
Discharge 
Amount 
+++ ++ +++ 
pH 6.5 5.0 5.5 
Odour + _ + 
Clue Cells + _ + 
Itching/burning _ _ + 
Lactobacilli growth _ + + 
Prescription Pro-vag-Health (7 
capsules) 
Pro-vag-Health (2 capsules) 
One each week 
Pro-vag-Health (2 
capsules) One each week 
Subjective Relief _ 20% Relief No Relief 
Side effects  None None 
“+” Present, “-“Absent 
In group II where women were using 
BASANT, 14 out of 20 women responded 
positively with healing of the symptoms. In 
group III in which women were treated 
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simultaneously with both BASANT and Pro-
vag-Health (NAUROZ), surprisingly nearly 
every woman except one had a positive 
response. In group IV, in which Placebo 
Capsules were used by the 20 women for 7 
days, only one woman showed regression of 
symptoms. Fig. 1 gives the four criteria on 
basis of which efficacy of the treatment were 
gauged. Table 3 is a summarized version of 
the observations in the 20 women enrolled in 
the NAUROZ group. Table 4 is the summary of 
the observations in the four groups of 80 
patients receiving various treatments. 
Statistical analysis was done to 
compare the proportion of patients in which 
regression of vaginosis occurred by different 
treatments as compared to control therapy. 
Analysis was carried out by Fisher’s exact 
test/ Chi square test. All 3 therapies caused 
statistically significant improvement 
(P<0.001) as compared to control. 
The Combination however was most effective 
(Table 4). 
Fig 1: An illustrative representation of typical woman receiving the treatment with 
combination of BASANT plus Pro-vag-Health. 
 (a) Relief from abnormal vaginal discharge 
             
On Enrollment     After Treatment 
(b) Disappearance of Clue cells: 
          
                             On Enrollment    After Treatment (Lactobacilli colonised) 
(c) Healing of fishy odour: 
Fishy Odour  No Fishy Odour 
(After KOH addition on slide)   (After KOH addition on slide)  
     On Enrollment        After treatment 
(d) pH of vagina restored to acidic range: 
      pH > 5  pH < 4.5 
On Enrollment   After treatment 
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Table 3: EFFECT OF TREATMENT WITH COMBINATION OF BASANT PLUS PRO-VAG-HEALTH PROBIOTICS 
Sl. 
No. 
Pt. Id VAGINAL DISCHARGE SYMPTOMS 
(Itching/Burning) 
  ODOUR  CLUE CELLS   pH LACTOBACILLI 
ISOLATED 
SUBJECT 
RELIEF 
  ENR Da
y 
10 
Da
y 
25 
Da
y 
60 
EN
R 
Da
y 
10 
Da
y 
25 
Da
y 
60 
EN
R 
Da
y 
10 
Da
y 
25 
Da
y 
60 
EN
R 
Da
y 
10 
Da
y 
25 
Da
y 
60 
EN
R 
Da
y 
10 
Da
y 
25 
Da
y 
60 
EN
R 
Da
y 
10 
Da
y 
25 
Da
y 
60 
 
3. BV-A-
109 
+++
+ 
+ _ _ ++ + _ _ +++ + _ _ +++ + _ _ 6.0 5.5 4.5 4.5 _ + + + Patient 
Satisfied 
7. BV-A-
112  
+++ + _ _ ++ _ _ _ +++ _ _ _ ++ _ _ _ 5.5 5.0 4.5 4.5 _ + + + Patient 
Satisfied 
11. BV-A-
114 
+++ ++ ++ ++ + + + + +++ ++
+ 
++ + +++ ++ ++ ++ 5.0 5.0 5.0  _ _ _ _ Patient not 
Satisfied 
15. BV-A-
121 
+++ + _ _ ++ _ _ _ ++ _ _ _ ++ _ _ _ 5.0 4.5 4.5 4.0 _ + + + Patient 
Satisfied 
19. BV-A-
122 
+++ + _ _ ++ _ _ _ ++ + _ _ +++ + _ _ 6.0 4.5 4.5 4.5 _ + + + Patient 
Satisfied 
23. BV-A-
123 
+++ + _ _ + _ _ _ +++ _ _ _ ++ _ _ _ 5.5 5.5 4.5 4.5 _ + + + Patient 
Satisfied 
27. BV-A-
127 
+++ _ _ _ + _ _ _ +++ _ _ _ ++ _ _ _ 5.5 4.5 4.5 4.5 _ + + + Patient 
Satisfied 
31. BV-A-
128 
+++ + _ _ ++ _ _ _ ++ _ _ _ +++ _ _ _ 5.5 5.0 4.5 4.0 _ + + + Patient 
Satisfied 
35. BV-A-
132 
+++
+ 
+ _ _ ++
+ 
_ _ _ +++ _ _ _ ++ _ _ _ 5.5 4.5 4.5 4.5 _ + + + Patient 
Satisfied 
39. BV-A-
134 
+++
+ 
+ _ _ ++ _ _ _ ++ _ _ _ +++ _ _ _ 5.5 4.5 4.5 4.5 _ + + + Patient 
Satisfied 
“+” PRESENT “-” NOT PRESENT “ENR” ENROLLMENT 
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Sl. 
No. 
  
Pt. Id 
VAGINAL DISCHARGE  SYMPTOMS 
(Itching/burning) 
ODOUR  CLUE CELLS  pH LACTOBACILLI 
ISOLATED 
 
SUBJECT 
RELIEF 
  ENR Da
y 
10 
Da
y 
25 
Da
y 
60 
EN
R 
Da
y 
10 
Da
y 
25 
Da
y 
60 
ENR Da
y 
10 
Da
y 
25 
Da
y 
60 
ENR Da
y 
10 
Da
y 
25 
Da
y 
60 
EN
R 
Da
y 
10 
Da
y 
25 
Day 
60 
EN
R 
Da
y 
10 
Da
y 
25 
Day 
60 
 
43. BV-
189 
+++
+ 
+ _ _ ++ _ _ _ +++ _ _ _ +++ _ _ _ 8.5 5.0 4.5 4.5 _ + + + Patient 
Satisfied 
47. BV-
190  
+++ + _ _ ++ _ _ _ ++ _ _ _ ++ _ _ _ 8.0 5.0 4.5 4.5 _ + + + Patient 
Satisfied 
51. BV-
191 
+++ _ _ _ ++
+ 
_ _ _ +++ _ _ _ ++ _ _ _ 7.0 5.0 4.5 4.0 _ + + + Patient 
Satisfied 
55. BV-
195 
+++ + _ _ + _ _ _ ++ _ _ _ +++ _ _ _ 7.5 4.5 4.5 4.0 _ + + + Patient 
Satisfied 
59. BV-
196 
+++ + _ _ ++ _ _ _ ++ _ _ _ ++ _ _ _ 7.5 5.0 4.5 4.5 _ + + + Patient 
Satisfied 
63. BV-
197 
+++ + _ _ ++ _ _ _ +++ _ _ _ +++ _ _ _ 8.5 5.0 4.5 4.5 _ + + + Patient 
Satisfied 
67. BV-
198 
+++ _ _ _ ++ _ _ _ ++ _ _ _ ++ _ _ _ 7.5 5.0 4.5 4.5 _ + + + Patient 
Satisfied 
71. BV-
200 
++ _ _ _ + _ _ _ ++ _ _ _ ++ _ _ _ 8.5 4.5 4.5 4.5 _ + + + Patient 
Satisfied 
75. BV-
201 
++ _ _ _ + _ _ _ ++ _ _ _ ++ _ _ _ 6.5 5.0 4.5 4.5 _ + + + Patient 
Satisfied 
79. BV-
203 
+++ + _ _ ++ _ _ _ ++ _ _ _ ++ _ _ _ 7.0 6.0 4.5 4.5 _ + + + Patient 
Satisfied 
“+” PRESENT “-” NOT PRESENT “ENR” ENROLLMENT 
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Table 4: SUMMARY OF RESULTS OF TREATMENT WITH EITHER PROBIOTICS, BASANT OR A 
COMBINATION OF BASANT AND PROBIOTICS TO CURE VAGINOSIS AND RESTORE 
REPRODUCTIVE HEALTH 
Group Name Improved (%)  
N=20 
P value 
Comparison with 
Placebo 
P value 
Comparison with 
BASANT+Probiotics 
Probiotics 65% P<0.001 P = 0.04 
BASANT 70% P<0.001 P = 0.09 
BASANT + Probiotics 95% P<0.001 - 
Placebo 5% - P<0.001 
Comparison with Fisher’s exact test 
DISCUSSION 
As pointed out in Introduction, vaginosis 
is a widely prevalent syndrome, 30% to 80% 
women in urban and rural areas are suffering 
from vaginosis. For cultural reasons they do not 
normally complain and consider it as a part or 
consequence of marriage and intercourse. This 
study was carried out in two major hospitals of 
Delhi where women coming for antenatal or 
fertility related problems were diagnosed to 
suffer from vaginosis. Normally these women 
are given treatment with antibiotics like 
Metronidazaole, Clindamycin plus Clotrimazole 
which in most cases give relief, even though it is 
not long lasting and recurrence of vaginosis is 
frequent. This problem is not only restricted to 
India but is also noted to occur in other 
countries. 
Treatment with antibiotics does not 
always restore the in-dwelling Probiotic 
lactobacilli in the vagina with the result that the 
vaginal pH of such patients is frequently above 
5.0 and they remain prone to contracting 
infections again. One of the objectives of the 
present trial was to ascertain whether the three 
strains of Lactobacilli previously isolated from 
the healthy vagina and short listed from 
amongst 80 strains on the basis of their high 
production of lactic acid, hydrophobicity and 
arginine deiminase activity do colonise in 
vagina. Another objective of the trial was to see 
whether a Polyherbal microbicide BASANT 
endowed with wide spectrum antimicrobial 
activity can replace the antibiotics currently 
prescribed. BASANT is competent to regress 
vaginosis though only in 14 out of 20 (70%) of 
women. BASANT capsules were well received 
with ease of insertion and lack of any side 
effects or adverse events. Thus the Polyherbal 
microbicide composed of purified quality 
controlled ingredients from traditionally used 
herbs, formulated as powder delivered in 
cellulose capsules, has the potential of use as an 
OTC product. Besides acting against the 
spectrum of aerobic and anaerobic 
microorganisms causing vaginosis, BASANT is 
endowed with pronounced inhibitory action 
against a number of sexually transmitted 
infections like Staphylococcus aureus, Neisseria 
gonohrreae, Chlamydia trachomatis, Candida 
spp, HPV and HIV. In an ongoing trial in women 
at early stage of Cervical dysplasia, when the 
causative HPV is not yet integrated in the 
genome, 30 applications of BASANT capsule, 
one each night, eliminated HPV and restored the 
cervical cytology and Pap smear to normal type. 
Although each one of the three selected 
Probiotic strains namely TRF#36 strain of 
Lactobacillus fermentum, TRF#8 strain of L. 
gasseri, and TRF#30 strain of L. salivarius is able 
to colonise in the vagina, administration of the 
combination of three (Pro-veg-Health) 
colonised in almost all women who received the 
triple combination. It took care of the person to 
person variability and sexual behaviour 
amongst women. 
Even though Probiotics or BASANT gave 
relief individually and were useful in many but 
not all, the Combination of the two NAUROZ was 
highly effective, 19 out of 20 taking a 
combination of BASANT and Pro-vag-Health 
Probiotics (NAUROZ) for seven days were fully 
cured in terms of the regression of vaginal 
discharge, pH returning to acidic range, absence 
of clue cells and lactobacilli colonised in the 
vagina.  
CONCLUSION 
These studies indicate the merit of using 
combination of a wide spectrum microbicide 
with Probiotics of meritorious properties, for 
regression of vaginosis & restoration of vaginal 
health. The combination has high efficacy of 
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curing vaginosis, bringing down the vaginal pH 
to acidic range accompanied by colonisation of 
Probiotic Lactobacilli. 
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